Ginkgo Bioworks (NYSE:DNA) Posts Quarterly Earnings Results, Beats Estimates By $0.15 EPS

Ginkgo Bioworks (NYSE:DNA) announced its quarterly earnings data on Wednesday. The company reported ($0.75) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.15, FiscalAI reports. Ginkgo Bioworks had a negative return on equity of 56.08% and a negative net margin of 215.41%.The company had revenue of $20.16 million during the quarter, compared to analyst estimates of $24.05 million.

Here are the key takeaways from Ginkgo Bioworks’ conference call:

• Revenue fell sharply: Q2 2026 revenue declined 48% year over year to $20 million, while adjusted EBITDA worsened to negative $36 million from negative $25 million.
• Q2 cash burn increased to $45 million from $38 million a year earlier, and excess leased-space costs rose to $14 million; the company nevertheless reaffirmed full-year 2026 cash-burn guidance of $125 million to $150 million.
• Ginkgo reported progress scaling Nebula, its Boston autonomous lab, to 105 racks and said it is operating 24/7 with roughly 30 unique protocols per day, potentially improving service economics and demonstrating the platform to prospective customers.
• The company announced autonomous-lab awards involving MIT, Caltech, the University of Maryland, and Northwestern, expanding its reach into academic research and potentially supporting future lab-equipment, software, and support revenue.
• Ginkgo said its ADME-One service attracted approximately 16 customers in its first six weeks and offers a drug-screening panel for $199, substantially below quoted Western and Chinese CRO pricing, although the company still needs to establish repeat demand and scale.

Ginkgo Bioworks Stock Down 8.6%

DNA traded down $0.81 during trading on Thursday, reaching $8.56. 1,714,936 shares of the company were exchanged, compared to its average volume of 1,159,808. Ginkgo Bioworks has a 12-month low of $5.37 and a 12-month high of $17.58. The company’s 50-day moving average is $8.82 and its two-hundred day moving average is $8.33. The company has a market cap of $559.50 million, a price-to-earnings ratio of -1.60 and a beta of 1.78.

Institutional Investors Weigh In On Ginkgo Bioworks

Several hedge funds and other institutional investors have recently modified their holdings of DNA. Raymond James Financial Inc. bought a new position in shares of Ginkgo Bioworks in the second quarter valued at approximately $29,000. Quarry LP bought a new stake in Ginkgo Bioworks during the 3rd quarter worth approximately $29,000. Daiwa Securities Group Inc. purchased a new stake in Ginkgo Bioworks in the 2nd quarter worth approximately $71,000. Atom Investors LP bought a new position in Ginkgo Bioworks in the 4th quarter valued at $105,000. Finally, Acadian Asset Management LLC bought a new position in Ginkgo Bioworks in the 1st quarter valued at $120,000. 78.63% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ginkgo Bioworks in a research report on Friday, July 17th. Wall Street Zen downgraded shares of Ginkgo Bioworks from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. One research analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Reduce” and an average price target of $8.50.

About Ginkgo Bioworks

Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.

The company’s services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.